Banque Cantonale Vaudoise Grows Stock Holdings in UiPath Inc. (NYSE:PATH)

Banque Cantonale Vaudoise raised its holdings in shares of UiPath Inc. (NYSE:PATH) by 67.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,786 shares of the healthcare company’s stock after acquiring an additional 10,829 shares during the quarter. Banque Cantonale Vaudoise’s holdings in UiPath were worth $339,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Intech Investment Management LLC raised its stake in shares of UiPath by 3.1% during the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock valued at $356,000 after purchasing an additional 426 shares during the period. Global Financial Private Client LLC increased its position in shares of UiPath by 9.3% during the first quarter. Global Financial Private Client LLC now owns 6,471 shares of the healthcare company’s stock valued at $144,000 after buying an additional 551 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of UiPath by 1.7% in the first quarter. Principal Financial Group Inc. now owns 36,772 shares of the healthcare company’s stock worth $834,000 after buying an additional 622 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of UiPath by 40.2% in the first quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock valued at $50,000 after acquiring an additional 632 shares during the period. Finally, Lindbrook Capital LLC grew its stake in UiPath by 46.0% during the first quarter. Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock valued at $46,000 after acquiring an additional 639 shares in the last quarter. Hedge funds and other institutional investors own 62.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on PATH. Barclays lowered their target price on shares of UiPath from $16.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Monday, August 19th. KeyCorp reissued a “sector weight” rating on shares of UiPath in a research note on Thursday, May 30th. Evercore ISI decreased their target price on UiPath from $27.00 to $13.00 and set an “in-line” rating on the stock in a research note on Thursday, May 30th. Morgan Stanley dropped their price target on UiPath from $25.00 to $15.00 and set an “equal weight” rating for the company in a research report on Thursday, May 30th. Finally, TD Cowen reissued a “hold” rating and set a $17.00 price objective (down previously from $28.00) on shares of UiPath in a report on Thursday, May 30th. Sixteen analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.94.

UiPath Stock Up 0.3 %

NYSE PATH opened at $12.88 on Tuesday. The firm has a market cap of $7.38 billion, a price-to-earnings ratio of -80.50 and a beta of 0.86. The company has a 50-day simple moving average of $12.19 and a two-hundred day simple moving average of $16.95. UiPath Inc. has a 12-month low of $10.37 and a 12-month high of $27.87.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.